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Abstract
Objective: The aim of this study was to provide evidence-based recommendations for omega-3
supplementation during pregnancy through a systematic review of level-1 data published on
this topic.
Methods: We reviewed all randomized-controlled trials (RCTs) including women who were
randomized to treatment with either omega-3 supplementation or control (placebo or no
treatment) during pregnancy and analyzed all the outcomes reported in the trials, separately.
We planned to evaluate the effect of omega-3 on: preterm birth (PTB); pre-eclampsia (PE) and
intrauterine growth restriction (IUGR); gestational diabetes; perinatal mortality; small for
gestational age (SGA) and birth weight; infant eye and brain development; and postpartum
depression.
Results: We identified 34 RCTs including 14 106 singletons and 2578 twins. These level-1 data
showed that omega-3 was not associated with prevention of PTB, PE, IUGR, gestational
diabetes, SGA, post-partum depression or better children development. Data about birth
weight, perinatal mortality and childhood cognitive outcome were limited. Women with
gestational diabetes who received omega-3 had significantly lower serum C-reactive protein
concentrations, low incidence of hyperbilirubinemia in newborns and decreased newborns’
hospitalization rate.
Conclusions: There was not enough evidence to support the routine use of omega-3
supplementation during pregnancy. Given the 73% significant decrease in perinatal death in
the singleton gestations who started omega-3 supplementation  20 weeks, further research is
needed. Large RCTs in multiple gestations and longer follow-up are also required.
Keywords
Meta-analysis, nutrition, perinatal death,
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Introduction
Omega-3 fatty acids (n–3), such as eicosapentaenoic (EPA)
and docosahexaenoic (DHA) acids are long-chain polyunsat-
urated fatty acids (LCPUFAs). These are essential polyunsat-
urated fatty acids (PUFAs) because the body cannot produce
them, and therefore must be obtained through the diet or
synthesized from their precursor alfa-linolenic acid. The
pregnancy is a time of increased risk for omega-3 deficiency
as they are used for the developing fetus [1–3] For this reason,
omega-3 supplementation is often recommended during
pregnancy [4,5].
The evidence of a positive association between omega-3
supplementation during pregnancy and maternal and neonatal
outcomes came originally from observational studies [6–8].
Olsen et al. in 1986 first suggested that omega-3 supplemen-
tation during pregnancy may lead to better pregnancy
outcomes by prolonging gestation [6]. Randomized-con-
trolled trials (RCTs) have been performed to assess if
omega-3 supplementation affects pregnancy outcomes, with
contradicting results [9–42]. The aim of this study was to
provide evidence-based recommendations for omega-3 sup-
plementation during pregnancy through a review of all level-1
data published on this topic.
Methods
The search strategy included the use of key words related
to ‘‘fish oil,’’ ‘‘long chain polyunsaturated fatty acids,’’
‘‘pregnancy,’’ ‘‘trial,’’ ‘‘randomized,’’ ‘‘docosahexaenoic,’’
‘‘eicosapentaenoic,’’ ‘‘prostaglandins,’’ ‘‘DHA,’’ ‘‘EPA’’
and ‘‘omega-3’’ in MEDLINE, Scopus, Sciencedirect,
ClinicalTrials.gov, the PROSPERO International Prospective
Register of Systematic Reviews, EMBASE and the Cochrane
Central Register of Controlled Trials from inception of each
database to March 2015. No restrictions for language or
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geographic location were applied. All published RCTs on
omega-3 supplementation during pregnancy were carefully
reviewed. Two reviewers (G. S. and V. B.) independently
performed the search and reviewed citations for potentially
eligible studies.
We reviewed all RCTs of women who were randomized to
either omega-3 supplementation or control (i.e. placebo or no
treatment) during pregnancy and analyzed all the outcomes
reported in the trials both in singleton and in multiple
gestations, separately. Quasi-randomized trials (i.e. trials in
which allocation was done on the basis of a pseudo-random
sequence, e.g. odd/even hospital number or date of birth,
alternation) were excluded. We planned separate analyses to
evaluate the effect of omega-3 supplementation on: spontan-
eous preterm birth (PTB) (i.e. PTB537 weeks); pre-eclamp-
sia (PE) and intrauterine growth restriction (IUGR) (i.e.
ultrasound estimated fetal weight510th percentile); gesta-
tional diabetes; perinatal mortality (i.e. either stillbirth or
neonatal death); small for gestational age (SGA) (i.e. birth
weight510th percentile for gestational age) and birth weight;
infant eye and brain development; and postpartum depression.
Two review authors (G. S. and V. B.) independently
assessed inclusion criteria, risk of bias and data extraction.
Disagreements were resolved by consensus. The overall risk
of bias in each included study was assessed using the criteria
outlined in the Cochrane Handbook for Systematic Reviews
of Interventions [43]. The overall review authors’ judgments
were categorized as ‘‘low risk’’, ‘‘high risk’’ or ‘‘unclear
risk’’ of bias [43]. Data from each eligible study were
extracted without modification of original data onto custom-
made data collection forms.
The data analysis was completed independently by two
authors (G. S., V. B.) using Review Manager 5.3
(Copenhagen: The Nordic Cochrane Center, Cochrane
Collaboration, 2014). The completed analyses were then
compared, and any difference was resolved with review of the
entire data and independent analysis. Statistical heterogeneity
between studies was assessed using the Higgins I2 statistics
[43]. In case of statistically significant heterogeneity
(I2 50%), the random effect model of DerSimonian and
Laird was used to obtain the pooled risk estimate, otherwise a
fixed-effect model was planned [43]. The summary measures
were reported as relative risk (RR) or as mean difference with
95% confidence interval (CI), with an RR51 indicating
treatment benefit. p values50.05 was considered statistically
significant.
The review was registered with the PROSPERO
International Prospective Register of Systematic Reviews
(registration No.: CRD42015017264). This systematic review
was reported following the Preferred Reporting Item
for Systematic Reviews and Meta-analyses (PRISMA) state-
ment [44].
Results
We identified 34 RCTs on omega-3 supplementation during
pregnancy (Table 1) [9–42]. Most of them came from
Northern Europe. The vast majority of women randomized
were singleton gestations (14 106 women), making analyses
possible for this population, while data were limited for
multiple gestations (2,578 women). Most of them had
a low overall risk of bias according to the Cochrane
Collaboration’s tool for assessing risk of bias in randomized
trials [43].
Figure 1 shows the flow diagram of information through
the different phases of the review. No quasi-randomized trials
were found during the search process.
Preterm birth (singleton gestations)
Nine RCTs including 3854 asymptomatic singleton gestations
without prior PTB evaluated the prophylactic treatment with
omega-3 supplementation in prevention of PTB [9–17]. A
recent meta-analysis of these nine RCTs showed that omega-3
was not associated neither with significant prevention of
PTB537 weeks (RR 0.90, 95% confidence interval (CI)
0.72–1.11; Figure 2) nor with improved neonatal outcomes
[45]. However, in the planned subgroup analyses of omega-3
started20 weeks and in the studies with low risk of bias, a
significant decrease in perinatal death was found (RR 0.27,
95% CI 0.09–0.79; Figure 3).
Two large placebo-controlled and well-designed RCTs
including 1080 women evaluated the efficacy of omega-3 in
prevention of recurrent PTB in singleton gestations with prior
PTB [27,28]. Pooled results of the two RCTs showed no
statistically significant decrease in the incidence of recurrent
PTB537 weeks (RR 0.81, 95% CI 0.59–1.12) and PTB534
weeks (RR 0.62, 95% CI 0.26–1.46), but showed longer
latency (mean difference 2.10 d, 95% CI 1.98–2.2) and higher
birth weight (mean difference 102 g, 95% CI 20.09–184.95)
compared with omega-3 group with the placebo one in
women with prior PTB [46]. We found no RCT assessed the
efficacy of omega-3 in prevention of PTB in women with
short cervical length.
Pre-eclampsia and intrauterine growth restriction
(singleton gestations)
Seven RCTs, including 2869 singleton gestations, evaluated
the efficacy of omega-3 supplementation during pregnancy in
prevention of PE or IUGR [10,11,26,27,29,31,41]. Four trials
enrolled high-risk singleton gestations (i.e. women with prior
PE or IUGR) [10,11,27,31], while the other three had low-risk
singleton gestations [26,29,41]. Three of these RCTs were
well-designed trials [10,11,27], including the largest one with
1477 women enrolled [27]. However, only one trial showed a
positive association between omega-3 and PE; it showed that
daily oral DHA supplementation during pregnancy reduced
the incidence of PE significantly in women with chronic
hypertension (RR 0.25, 95% CI 0.09–0.69) [31].
A Cochrane review, including six trials on high-risk and on
low-risk pregnancies [10,11,26,27,29,41], showed a small but
significant increase in the mean length of gestation (mean
difference 2.55 d, 95% CI 1.03–4.07), but no significant effect
in prevention of PE (RR 0.86, 95% CI 0.59–1.27) or IUGR
(RR 1.13, 95% CI 0.96–1.34) [47].
Another well-designed trial, including 533 healthy low-
risk singleton gestations, showed that omega-3 supplementa-
tion during pregnancy had no statistically significant effect on
blood pressure comparing to no treatment (RR 0.48, 95% CI
0.22–1.06) [25].
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Gestational diabetes
Only one RCT evaluated the effect of omega-3 on gestational
diabetes [42]. This study, including only 54 singleton
gestations, showed that women with gestational diabetes
who where randomized to DHA group had a significantly
lower serum C-reactive protein concentrations (mean differ-
ence1158.00 ng/mL, 95% CI2217.45 to98.55), low
incidence of hyperbilirubinemia in newborns (RR 4.33, 95%
CI 1.03–18.19) and decreased newborns’ hospitalization rate
(RR 4.33, 95% CI 1.03–18.19). However, no effect was
noticed on the incidence of cesarean delivery (RR 1.44, 95%
CI 0.88–2.37), macrosomia (RR 6.27, 95% CI 0.37–124.61)
and polyhydramnios (RR 6.27, 95% CI 0.37–124.61) and on
birth weight (mean difference13.00 g, 95% CI55.31–
29.31). We found no RCT assessed the efficacy of omega-3 in
prevention of gestational diabetes in women without gesta-
tional diabetes.
Perinatal mortality (singleton gestations)
Eight RCTs evaluated the efficacy of omega-3 supplementa-
tion during pregnancy in prevention of perinatal mortality
with contradicting results [7–9,13,15,16]. The pooled risk
estimate showed no significant difference in the incidence of
perinatal mortality (RR 0.61, 95% CI 0.30–1.24).
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Figure 1. Flow diagram of studies identified in the systematic review
(Prisma template [Preferred Reporting Item for Systematic Reviews and
Meta-analyses]). RCTs, randomized controlled trials.
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Pooled results from trials in which supplementation
started 20 weeks [10,16,17], including the largest and
best-designed one [16], showed a 73% significant decrease
in perinatal death, which was consistently defined as the sum
of still birth and neonatal death (RR 0.27, 95% CI 0.09–0.79;
Figure 3) [45].
Small for gestational age and birth weight
(singleton gestations)
Omega-3 supplementation during pregnancy was not asso-
ciated with prevention of SGA (RR 1.13, 95% CI 0.96–1.34)
or low birth weight (RR 1.00, 95% CI 0.88–1.12), but
was associated with statistically significantly higher birth
weight (mean difference 47.24 g, 95% CI 1.05–93.44)
[10,11,26,27,29,39,47]. Two trials showed that DHA supple-
mentation during pregnancy could result in larger head
circumferences (mean difference 0.5 cm, 95% CI 0.11–0.91)
[18,19].
Pooled result from three RCTs, including 575 singleton
gestation with prior birth weight55th percentile for gesta-
tional age [10,11,27], showed that omega-3 did not prevent
recurrent birth weight55th percentile for gestational age (RR
1.13, 95% CI 0.83–1.54; Figure 4) [48].
Infant eye and brain development
(singleton gestations)
Only two RCTs including 312 singleton gestations investi-
gated the effect of maternal omega-3 supplementation on
vision after birth [12,15]. A meta-analysis of the two RCTs
showed no differences either in maturity of the retina at 1
week of age, or in visual function measured by visual evoked
potentials to flash and pattern reversal stimuli at birth and at
10 and 26 weeks of age [49].
Data about neonatal development were derived mostly
from observational studies. These studies generally demon-
strated that DHA supplementation during pregnancy was
Figure 2. Forest plot for preterm birth less than 37 weeks in women without prior preterm birth. PTB, preterm birth; M–H, Mantel–Haenszel test; CI,
confidence interval.
Figure 4. Forest plot for small for gestational age in women with small for gestational age. SGA, small for gestational age; M-H, Mantel–Haenszel test;
CI, confidence interval.
Figure 3. Forest plot for perinatal death in women who started omega-3 supplementation 20 weeks. Death, perinatal death; M–H, Mantel–Haenszel
test; CI, confidence interval.
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associated with improved neurodevelopmental outcomes in
the child [49–52]. Level-1 data about brain development were
controversial [16,17,20,37,41]. One trial showed that children
born to the mothers supplemented with omega-3 had a 4%
point advantage in scores on the Kaufman Assessment
Battery for Children (K-ABC) [16], and in 2004 Colombo
et al. reported that infants whose mothers had omega-3
supplementation during pregnancy showed less distractibility
in the second year [20]. In 2011, Escolano-Margarit et al.
concluded that a daily supplementation of DHA and EPA
during pregnancy could lead in a better neurological outcome
at 5.5 years of age [17]. Recent large and well-designed RCTs,
that followed infants up to age 18 months, however, found no
difference in cognitive and language scores and in attention
and working memory between offspring of singleton gesta-
tions supplemented with DHA during pregnancy and those
who received placebo [37,41].
Post-partum depression (singleton gestations)
Epidemiologic data showed that low seafood intake during
pregnancy correlated with higher levels of depressive symp-
tom during pregnancy [51,53]. However, the only RCT
available (including 2399 singleton gestations) failed to
demonstrate a clear and statistically significant benefit of
omega-3 supplementation during pregnancy in preventing
depressive post-partum symptoms (RR 0.85, 95% CI 0.70–
1.02) [16].
Multiple gestations
One well-designed placebo-controlled multicenter trial
reported data on multiple gestations, including 579 asymp-
tomatic twins [27]. In this study, the authors found no benefits
of omega-3 supplementations regarding PE, SGA, birth
weight or PTB. Furthermore, twins randomized to omega-3
group delivered at the same gestational age of placebo group.
Another trial, including 1999 twins, showed no benefit of
omega-3 supplementation in prevention of PE. However, this
study had high-risk of bias and reported no information about
the inclusion criteria [33]. No separate data about triplet
gestations were available in the literature.
Discussion
We identified 34 RCTs on omega-3 supplementation during
pregnancy [9–42]. These level 1-data showed that omega-3
supplementation during pregnancy was not associated with
prevention of PTB, PE, IUGR, SGA or post-partum depres-
sion. Data about perinatal death, birth weight and neuro-
logical children development were still limited.
Our study has many strengths. One is the inclusion of only
RCTs. To our knowledge, no prior systematic review on
omega-3 during pregnancy is as large, up-to-date or compre-
hensive. We reviewed all the RCTs published on omega-3
supplementation during pregnancy and analyzed all the
outcomes reported in these studies providing evidence-based
recommendations for omega-3 supplementation during preg-
nancy. Prior meta-analyses [45,46,48] evaluated only few
specific outcomes each (i.e. PTB, SGA, LBW, IUGR), while
others were not analyzed at all (e.g. PE, gestational diabetes,
brain development, maternal depression). Moreover, the prior
meta-analyses included only singleton gestations while we
included also multiple gestations in the current article.
There are several limitations to our review. Search
strategies for retrieving RCTs and meta-analyses in electronic
databases are limited and this could have influenced our
findings. The included studies came from various regions of
the world so the level of dietary intake of omega-3 could not
be controlled for. Many of the trials reported only biochemical
outcomes (Table 1). Data on multiple gestations were limited.
We carried out a systematic review and not a meta-analysis
and so publication bias and sensitivity analyses were not
performed.
The use of omega-3 supplementation during pregnancy has
been studied as a possible strategy to prevent PTB, PE, post-
partum depression, as well as to increase birth weight; and so
far, no potential adverse or toxic effects have been reported in
the literature. The theories behind the studies were based on
the observations of longer gestation in communities with high
fish oil consumption [6,54]. A recent study showed that
women who received low-dose fish intake during pregnancy
had a higher risk of PTB [55]. The biological plausibility is
that omega-3 fatty acids depress the synthesis of the
prostaglandins (PGs) E2 and may delay initiation of cervical
ripening by switching the PGs synthetic pathways from PGE2
to PGE3, which have anti-inflammatory effects [56–58]. PGE2
such as PGE2a, which derive enzymatically from n–6 PUFA
(i.e. arachidonic acid), play a major role in the uterine
contractions and biophysical changes associated with cervical
ripening [59,60]. Figure 5 showed the prostaglandins syn-
thetic pathways and the omega-3 mediated switching from
PGE2 to PGE3 synthetic pathways. The different effects of
PGs seem to be linked with the position of the last double
bond (n–6 versus n–3): PGE2 derived from arachidonic acid
(n–6 PUFA), while PGE3 from EPA acid (n–3 PUFA)
(Figure 6) [56]. Moreover, omega-3 fatty acids given before
the placentation increase placental labyrinthine antioxidant
capacity [56,57]. This may explain the significant decreases in
perinatal death in trials who started omega-3 20 weeks [45].
For this reason, we might argue that effectiveness could be
greater if supplementation was started in the first trimester.
According to the Food and Agriculture Organization of the
United Nations (FAO), International Society for the Study of
Fatty Acids and Lipids (ISSFAL), World Association of
Perinatal Medicine, Australian & New Zealand Health
Authorities and European Food Safety Authority, daily
intake of omega-3 supplementation is recommended during
pregnancy [4,61–65]. However, level-1 data from this
systematic review indicated no enough evidence to support
the routine use of omega-3 supplementation during
pregnancy.
Given the 73% significant decrease in perinatal death in
the singleton gestations who started omega-3 supplementation
 20 weeks [45], further research is needed. Indeed, even
with a summary estimate from 2462 women the ability to
discern differences in perinatal death is impaired by type II
error and until proper power trials are performed, this
intervention should not be routinely available. We observed
that with an a of 0.05 and 80% power, a sample size of 1850
patients in each group is required to detect a 73% reduction in
2394 G. Saccone et al. J Matern Fetal Neonatal Med, 2016; 29(15): 2389–2397
perinatal death. Large RCTs in multiple gestations and longer
follow-up are also required.
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